



03-06-08

1644

1fr

PTO/SB/21 (01-08)

Approved for use through 01/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/527,937-Conf. #2366
	Filing Date	December 20, 2005
	First Named Inventor	Nehal MOHAMED
	Art Unit	1644
	Examiner Name	F.P. Vandervegt
Total Number of Pages in This Submission	Attorney Docket Number	ELI-038US

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Return Receipt Postcard PTO form SB/08 Certificate of Mailing Copies of Four (4) References
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Megan E. Williams		
Date	March 5, 2008	Reg. No.	43,270



Express Mail Label No. EM 067555951 US Dated: March 5, 2008

Docket No.: ELI-038US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Nehal Mohamed *et al.*

Application No.: 10/527,937

Confirmation No.: 2366

Filed: December 20, 2005

Art Unit: 1644

For: BISPECIFIC MOLECULE COMPRISING AN  
ANTI-CR1 ANTIBODY CROSS-LINKED TO  
AN ANTIGEN-BINDING ANTIBODY  
FRAGMENT

Examiner: F.P. Vandervegt

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents, cited in a European Office Action issued February 14, 2008, during the prosecution of Application No. 03786512.8 - 2402, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Office Action and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

Applicants also cite the following commonly owned co-pending applications directed to related subject matter:

10/843,038, filed on 5/10/04, entitled “Non-human Animals Expressing Heterologous Complement Receptor type 1 (CR1) Molecules on Erythrocytes and Uses Therefor”;

10/812,636, filed on 3/29/04, entitled “Methods and Compositions for Conversion of Antibody Activity”;

11/263,569, filed on 10/31/05, entitled “Use of CR1-binding Molecules in Clearance and Induction of Immune Responses”;

10/515,525, filed on 1/8/07, entitled “Immunogenicity-reduced Anti-CR1 Antibody and Compositions and Methods of Treatment Based Thereon”;

10/415,840, filed 11/3/03, entitled “Method of Producing Bispecific Molecules by Protein Trans-Splicing”;

10/258,650, filed 3/3/04, entitled “Bispecific Molecules and Uses Thereof”;

10/472,051, filed 6/17/04, entitled “Polyclonal Populations of Bispecific Molecules and Methods and Production and Uses Thereof”;

10/527,936, filed 2/28/06, entitled “Production of Bispecific Molecules Using Polyethylene Glycol Linkers”;

10/514,547, filed 11/10/04, entitled “Purified Composition of Bispecific Molecules and Methods of Production”;

60/848,480, filed 9/28/06, entitled “Anti-Anthrax Antibody, Formulations Thereof, and Methods of Use”;

60/859,240, filed 11/14/06, entitled “Improved Staphylococcal Protein A Binding Molecules, Heteropolymers Comprising the Same and Methods of Their Use”;

and

60/918,413, filed 3/16/07, entitled “Purification of Heteropolymers Using Hydrophobic Interaction Chromatography”.

Applicants also cite the following commonly owned co-pending application:

PCT/US03/29065, filed 9/16/03, entitled “Bispecific Molecule Comprising an Anti-CR1 Antibody Cross-Linked to an Antigen-Binding Antibody Fragment”.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he is invited to call the undersigned who will be happy to supply them.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).


Furthermore, in accordance with 37 CFR 1.704(d), Applicants note that to our knowledge this communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of this statement.


The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. ELI-038US.

Dated: March 5, 2008

MEW/MBC/mch

Respectfully submitted,

By   
Megan E. Williams  
Registration No.: 43,270  
LAHIVE & COCKFIELD, LLP  
One Post Office Square  
Boston, Massachusetts 02109-2127  
(617) 227-7400  
(617) 742-4214 (Fax)  
Attorney/Agent For Applicant



Application No. (if known): 10/527,937


Attorney Docket No.: ELI-038US

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EM 067555951 US in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on March 5, 2008  
Date

  
Signature

Megan E. Williams

Typed or printed name of person signing Certificate

43,270  
Registration Number, if applicable

(617) 994-0761  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard  
Transmittal (1 page)  
Supplemental Information Disclosure Statement (4 pages)  
PTO form SB/08 (4 References) (1 page)  
Copies of Four (4) References